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Background: In North America, Borrelia burgdorferi is the causative bacterial agent of canine Lyme borreliosis and is
transmitted following prolonged attachment and feeding of vector ticks, Ixodes scapularis or Ixodes pacificus. Its
prevention is predicated upon tick-avoidance, effective on-animal tick control and effective immunization strategies.
The purpose of this study is to characterize dogs that are newly seropositive for Borrelia burgdorferi infection in
relation to compliant use of a recombinant OspA canine Lyme borreliosis vaccine. Specifically, Preventive Fractions
(PF) and Risk Ratios (RR) associated with the degree of vaccine compliancy (complete versus incomplete) are
determined.
Methods: 6,202 dogs were tested over a five year period in a single veterinary hospital utilizing a non-adjuvanted,
recombinant OspA vaccine according to a 0, 1, 6 month (then yearly) protocol. Rates of newly acquired “Lyme-positive”
antibody test results were compared between protocol compliant and poorly compliant (incompletely and/or
non-vaccinated) dogs.
Results: Over the five-year span, one percent (range 0.39 - 1.3) of protocol compliant vaccinated, previously antibody
negative dogs became seropositive for infection. Approximately twenty-one percent (range 16.8 – 33.3) of incompletely
vaccinated dogs became positive for infection-specific antibodies. The Preventative Fraction for testing positive for
antibodies specific for infection with Borrelia burgdorferi in any given year based on optimal vaccine compliance was,
on average, 95.3% (range 93.29 - 98.08). The Risk Ratio for becoming infected with Borrelia burgdorferi antibodies in any
given year if vaccine non-compliant was 21.41 (range 14.9 – 52.1). There was a high statistically significant relationship
(p = <0.0001) in the observed data in terms of vaccination protocol compliance and the probability of Borrelia
burgdorferi infection in each of the five years under study.
Conclusions: The recombinant outer surface protein A (rOspA) vaccine for dogs is highly effective in preventing new
seropositive cases of Borrelia burgdoferi infection over a five-year period in dogs living in an endemic area. Dogs that
were vaccine protocol-compliant were significantly less likely to become infected (as indirectly assessed by antibody)
with the agent of canine Lyme borreliosis as measured by Preventive Fraction and Risk Ratio calculations.
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Canine lyme borreliosis
In the United States, canine Lyme borreliosis was first de-
scribed in 1984 [1]. Infection and disease results from the
successful transmission of the spirochete, Borrelia burg-
dorferi, from an infected tick to a dog [1]. The ecology,
biology and disease manifestations of Borrelia burgdorferi,
as well as its sister species in Europe (B. afzellii and B. gar-
inii) and its tick vector in the Ixodes genus have been thor-
oughly described elsewhere in the literature [2-5].
Four brands, representing two distinct classes of vac-
cines, are available for use in dogs in the United States
for the purpose of preventing Lyme borreliosis. To date,
five placebo-controlled laboratory studies pertaining to
commercialized whole-cell Lyme borreliosis bacterins
and recombinant OspA vaccines for dogs have been
published [6-10]. In addition, four published papers have
explored the performance of canine Lyme disease vac-
cines in the private, clinical practice setting [11-14].
Testing parameters, including time frames, site loca-
tions, and sample size were dissimilar within all of these
studies so direct comparison of vaccine efficacy are not
feasible. While whole cell bacterins are appreciably effi-
cacious depending on which parameter you are interested
in, reports have described the occasional occurrence of
post-vaccinal “Lyme-like” clinical signs in some recently
vaccinated, uninfected dogs [7,15,16]. These signs have
been putatively associated with the wider array of proin-
flammatory outer surface Borrelia proteins contained
within bacterins [15,16]. In an effort to decrease the ad-
verse reaction profile and remedy the occasional diagnos-
tic conundrums posed by whole cell bacterins for Lyme
borreliosis, a Type I recombinant OspA (rOspA) subunit
extract was licensed and marketed for canine use in the
United States in 1996. This vaccine was the first Lyme
disease vaccine to be licensed by the USDA demonstrat-
ing a 1-year duration of immunity (DOI) after use of a
natural tick challenge model [9]. Efficacy of the rOspA
vaccine was based on the ability of the vaccine to pre-
vent spirochete transmission as assessed by re-isolation
of spirochetes from skin biopsies of vaccinated and
non-vaccinated control dogs. In 2000, a randomized,
placebo-controlled study explored the effectiveness of
the recombinant OspA vaccine (Recombitek® Lyme,
Merial) and demonstrated that non-adjuvanted recom-
binant OspA completely prevented B. burgdorferi infec-
tion in vaccinated dogs [10].
The following analysis offers a comprehensive look at
the performance of the recombinant OspA Lyme-disease
vaccine over five years of continuous use in a busy, 3-
doctor small (companion) animal practice in Wiscasset,
Maine. Since 2009, the practice has been vaccinating
dogs to prevent canine Lyme borreliosis utilizing the
non-adjuvanted, recombinant OspA subunit vaccine(Recombitek® Lyme, Merial) using an alternate dose veter-
inary protocol first suggested by Töpfer and Straubinger
[17]. These authors observed that “regardless of vaccine
used, the third vaccination induced significantly higher
antibody levels.” This protocol modification suggestion
was predicated on earlier work in human medicine
showing that the addition of a third dose of vaccine
within 6 months of starting the basic immunization
protocol could increase the proportion of protected in-
dividuals by a factor of almost 2-fold [18]. With em-
phasis on preventing canine Lyme borreliosis utilizing
the Töpfer-Straubinger vaccine protocol recommenda-
tions, this Maine veterinary practice advanced the initial
annual Lyme disease booster vaccine forward in time by
six months. The goal was to raise antibody levels to
their maximum more quickly within a dog’s first year
and thus they adopted the 0, 1, 6 month vaccine proto-
col instead of the traditional 0, 1, 12 month framework.
Accordingly, the veterinary hospital described in this
paper chose to include the recombinant OspA vaccine
as a CORE vaccine in their vaccine repertoire beginning
at 9 weeks of age, utilize a modified protocol and to
booster yearly in order to minimize the rate of new B.
burgdorferi infections in their canine patients. Diagnos-
tic assessment of Lyme ‘positive’ or ‘negative’ was made
using a popular test kit (SNAP®) manufactured by
IDEXX Laboratories. SNAP® is a proprietary rapid,
patient-side, lateral flow ELISA technology platform
that can detect antibody or antigen to a variety of
vector-borne parasites including C6 antibody to Borre-
lia burgdorferi, antibody to Ehrlichia canis, and antigen
of the canine heartworm Dirofilaria immitis (SNAP®
3Dx). Currently, antibodies to Anaplasma phagocyto-
philum and Ehrlichia ewingii can also be detected
(SNAP® 4Dx Plus). Further information pertaining to
product validation, testing and sensitivity/specificity can
be read elsewhere [19].
Methods
From 2009–2010, the hospital utilized SNAP 3Dx; from
2011–2012, SNAP 4Dx; and for 2013, SNAP 4Dx Plus;
the change in kit-type usage over time was the result of
increased pathogen testing capabilities by the kit itself
and each successive new product was incorporated soon
after market entry. The analysis of new Lyme infection
rates in vaccinated versus incompletely vaccinated dogs
was conducted annually at the conclusion of each year
beginning in 2009 until the end of 2013. Utilizing the
hospital’s veterinary management software (AVImark®,
Piedmont, MO), the results of all SNAP tests conducted
in dogs during the analysis year were tallied. Dogs that
tested SNAP positive for infection-specific B. burgdor-
feri-antibody were characterized according to vaccine
status and ‘age’ of their positive-status. For the analysis,
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“AGE”: A ‘NEW’ SNAP B. burgdorferi-infection positive
result (‘blue-dot’) was defined as a positive-test on a dog
that had tested negative on its most previously recorded
test. An ‘OLD’ SNAP Bb infection-positive was defined
as a repeat positive-test in a dog that also tested positive
on its most recent previous test. For purposes of this
retrospective study, dogs labelled as ‘OLD-positive’ were
not counted in the analysis of new infection rates in the
universe of vaccinated or non-vaccinated dogs within
that year. VACCINE STATUS: A ‘FULLY‘ vaccinated
dog was defined as a dog that had adhered to the hos-
pital vaccine recommendation for interval and compli-
ance for at least one year following a negative SNAP test
for B. burgdorferi antibodies. An ‘INCOMPLETELY vac-
cinated’ dog was segmented into the degree of incom-
pleteness. ‘PARTIALLY vaccinated’ was defined as
having received an initial vaccine with no boosters or
having completed its first series of two immunizations
with no subsequent booster. ‘NON-VACCINATED’ was
defined as having had no vaccines in its life or being
greater than 15 months beyond its regularly scheduled
yearly booster.
Analysis of new-positive infection rates
New SNAP B. burgdorferi-infection positive test results
were sorted based on the occurrence in the ‘Fully’ vacci-
nated, protocol-compliant group and the ‘incompletely’
vaccinated/non-vaccinated dogs. For the purpose of this
study, Infection rate (IR) differences were determined
by examining the proportion of new-positive test results
in fully vaccinated dogs amongst all fully vaccinated dogs
tested that year. Likewise, the number of new-positive
test results in incompletely vaccinated dogs (either par-
tial or non-vaccinated) was compared to the total of all
incompletely vaccinated dogs.
Risk Ratio(RR), the ratio of the probability of an
event (for example, developing a positive test) occurring
in an incompletely vaccinated group to the probability of
the event occurring in a comparison group (Fully-vacci-
nated group), were calculated for each year 2009–2013
according to the following equation [20].
Risk Ratio ¼ CIuð Þ = CIeð Þ
[where CIu is the cumulative incidence in the group
‘unexposed’ to Full vaccination and CIe is the cumulative
incidence in the group ‘exposed’ to Full vaccination].
Preventive Fraction (PF) for Benefit of Vaccination,
the percentage of infection reduction in the group ex-
posed to Full vaccination that can actually be attributed to
the ‘benefit of full vaccine exposure’, was calculated each
year by dividing the risk reduction between two groups
(incidence in unexposed (incompletely vaccinated) minusincidence in exposed (Fully vaccinated) group by the inci-
dence in the unexposed (expressed as a percent) according
to the following equation [20].
Preventive Fraction ¼ PF ¼ CIuð Þ − CIeð Þ½  = CIuð Þ x 100
[where CIu is the cumulative incidence in the group
‘unexposed’ to Full vaccination and CIe is the cumulative
incidence in the group ‘exposed’ to Full vaccination].
Results
During the five years of analysis (2009–2013), 6,202
SNAP® tests were completed on 4,551 well vaccinated
and 1,651 incompletely vaccinated dogs that had previ-
ously been characterized as either SNAP ‘positive’ or
‘negative’ (prior to study onset). In total, 835 tests
(13.5%) were positive indicating the presence of C6 anti-
bodies specific for infection with Borrelia burgdorferi.
Inspection of patient records revealed that 432 of the
positive tests were in dogs that had also tested positive
on their most recent previous test, therefore labeled as
‘OLD’ positives, and were excluded from the exercise of
determining the rate of new infections in vaccinated dogs.
Four hundred three dogs were NEW positives in the year
tested (had tested negative on their most recent previous
test), and made up 6.5% of all SNAP tests performed. In
the population of 6,202 dogs tested during 2009–2013,
4551 were fully vaccinated against canine Lyme borreliosis
and compliant with hospital vaccine-protocol recommen-
dations [Table 1]. There were 46 new positive tests among
these fully vaccinated dogs. One thousand six hundred
fifty one tests occurred in incompletely vaccinated dogs
and among these, 357 were newly positive.
The summary of the cumulative test results (2009–
2013) is displayed [Table 2]. The conditional probabilities
for each vaccination condition are displayed within paren-
theses under the counts. Given that a dog is fully vacci-
nated, the probability of this dog testing positive in our
sample is 1.01%. Similarly, given a dog is incompletely vac-
cinated, the probability of this dog testing positive in our
sample is 21.62% [Table 2]. This appears to be a large
practical difference in the percentage of dogs testing posi-
tive. However, because dogs are supposed to be tested an-
nually for Lyme borreliosis, it is likely that the same dogs
are being tested in different years. Therefore, in order to
avoid artificially increasing the sample size and introdu-
cing dependence into the observations (since results from
one dog may be related across different years), data were
analyzed in yearly increments [21].
Statistical analysis
The summary of test results for each year beginning
2009 through 2013 is displayed [Table 3]. For 2009, the
Chi-squared test statistic is 130.95 with a corresponding
Table 1 Tabulation of yearly testing results for antibodies directed against C6 antigen of Borrelia burgdorferi in dogs
utilizing the SNAP® 3Dx® or 4Dx® test kit
2009 2010 2011 2012 2013 Cumulative
SNAP tests utilized 1391 1346 1266 1127 1072 6202
SNAP B. burgdorferi-infection positive results 170 208 156 154 147 835
Old POS (+) 88 103 85 75 81 432
New POS (+) 82 105 71 79 66 403
Vaccine compliance status of tested dogs
Fully vaccinated dogs tested 970 1053 933 833 762 4551
New POS (+) 11 11 10 11 3 46
Negative (−) 959 1042 923 822 759 4505
Incompletely vaccinated dogs tested (also includes non-vaccinated) 421 293 333 294 310 1651
Total new (+): (includes dogs with unknown vaccine status)* 71 94 61 68 63 357
New POS (+) among NON-vaccinated 56 76 55 55 49 291
New POS (+) among partially vaccinated 15 18 6 13 14 66
Negative (−) 350 199 272 226 247 1294
*Dogs with unknown vaccine status grouped (conservatively) with ‘Incompletely Vaccinated Group’: 2009 (12); 2010 (11), 2011 (0), 2012 (0), 2013 (1).
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is truly no relationship between the SNAP test results for
fully and incompletely vaccinated groups, the probability
of collecting a sample with a relationship as strong as the
one in our sample is less than 0.0001 [21]. For 2010 –
2013, the Chi-squared test statistics were 307.01, 137.89,
158.56, and 151.47, respectively with a corresponding p-
values less than 0.0001 for each statistic [21].
The Risk Ratio (RR) describing the probability of Borrelia
burgdorferi infection (as determined by SNAP) in incom-
pletely vaccinated dogs compared to ‘fully’ vaccinated dogs
between 2009 and 2013 averaged 21.4 (range 14.8-52.1)
[Table 3]. The Preventative Fractions (PF) for prevention of
a positive test result for each year beginning in 2009
through 2013 were 93.29, 96.76, 94.16, 94.29, 98.08, re-
spectively [Table 3].
Discussion
Four different canine Lyme borreliosis vaccines repre-
sented by six distinct brand names have been licensed byTable 2 Cumulative summary of SNAP test results for
Borrelia burgdorferi-specific antibodies in completely and
incompletely vaccinated dogs (2009–2013)
Positive Negative Total
Completely vaccinated* 46 4505 4551
(1.01%) (98.99%)
Incompletely vaccinated* 357 1294 1651
(21.62%) (78.38%)
Total 403 5799 6202
*See working definition of completely and incompletely vaccinated dogs in
Methods section.the USDA from 1992–2009. Immunizing against canine
Lyme borreliosis can be achieved by delivering either a
whole-cell bacterial lysate (bacterin) or a recombinant
subunit vaccine containing Outer-surface protein A
(OspA). In the current study, the recombinant OspA
vaccine was chosen for its reported efficacy and safety
profile and was recommended by the veterinary hospital
as a ‘CORE’ vaccine for all dogs in 2009–2013. In each
year analyzed, the risk of a dog testing seropositive for
infection with Borrelia burgdorferi was greatly influenced
by vaccine status; on average, over the 5-year study
period just 1.01% (range of 0.39 - 1.32%) of fully vacci-
nated dogs exhibited evidence of a newly acquired infec-
tion while 21.62% (range 16.8 – 32.08%) of incompletely
vaccinated dogs experienced a new infection [Table 3].
Using the modified frequency vaccination protocol
wherein the scheduled first yearly booster was adminis-
tered 6-months early, no adverse events were reported.
Using Risk Ratio calculations, incompletely vaccinated
dogs were between 14 and 52 times more likely to become
seropositive for B. burgdorferi infection compared to their
‘fully’ vaccinated cohorts [Table 3]. In terms of a dog be-
coming newly positive for B. burgdorferi-specific anti-
bodies (an indirect measure of infection), the Preventative
Fraction when using the rOspA vaccine ranged from
93.29% in 2009 and 98.08% in 2013 [Table 3]. One limita-
tion of this analysis is that the effect of tick preventative
use (acaracides) between fully and incompletely vaccinated
dogs was not determined. One could hypothesize that
those dogs most likely to complete their vaccine series
and remain vaccine protocol-compliant might be dogs
with owners who are more likely to purchase tick control.
Even if both groups purchased tick preventative products,
Table 3 The profile of a new-positive SNAP test result for Borrelia burgdorferi infection, including preventative fraction
and risk ratio assessment among incompletely and completely vaccinated dogs
2009 2010 2011 2012 2013
Percent (+) of all tests run 12.22% 15.45% 12.30% 13.70% 13.70%
NEW (+) as % of all tests run 5.90% 7.86% 5.60% 7.01% 6.10%
Profile of a NEW (+) out of ALL new (+)’s
Incomplete-vaccination 86.59% (71/82) 89.52% (94/105) 85.92% (61/71) 86.08% (68/79) 95.45% (63/66)
Full-vaccination 13.41% (11/82) 10.48% (11/105) 14.08% (10/71) 13.92% (11/79) 4.55% (3/66)
Infection rate (IR) based on vaccine status*:
ALL incomplete-vaccination 16.86% (71/421) 32.08% (94/293) 18.32% (61/333) 23.13% (68/294) 20.32% (63/310)
Complete-vaccination 1.13% (11/970) 1.04% (11/1053) 1.07% (10/933) 1.32% (11/833) 0.39% (3/762)
Negative infection rate based on vaccine status
ALL incomplete-vaccination 83.14% (350/421) 67.92% (199/293) 81.68% (272/333) 76.87% (226/294) 79.68% (247/310)
Complete-vaccination 98.87% (959/970) 98.96% (1042/1053) 98.93% (923/933) 98.68% (822/833) 99.61% (759/762)
Chi-square test statistic 130.95 307.01 137.89 158.56 151.47
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Preventative fraction (PF) against infection** 93.29% 96.76% 94.16% 94.29% 98.08%
Risk ratio (RR)*** 14.92 30.85 17.12 17.52 52.10
*Infection Rate = No. positive in vaccine status category/all dogs tested in that category. NOTE: All dogs other than those testing New (+) had (−) tests.
**PF = [(Incidence of Event in Untreated – Incidence of Event in Treated)/Incidence of Event in Untreated] × 100.
***Risk Ratio = % Infected when incompletely vaccinated/% infected when completely vaccinated.
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purchased, on average, more doses throughout the year.
While additional analysis of the database may be useful to
detect whether the variable of tick control played a role in
Lyme-seropositive rates, the vast majority (>80%) of all ca-
nine patients within the hospital database receive less than
9 months of tick protection each year, regardless of their
vaccine status. Given that infected Ixodes scapularis can
transmit Borrelia burgdorferi whenever they attach to a
suitable host, regardless of season, the influence of tick
control (or lack thereof) between well vaccinated and in-
completely vaccinated may be minimal. Beyond tick con-
trol, perhaps an analysis of newly positive SNAP tests by
owner zip codes would reveal that B. burgdorferi infection
pressure is greater in certain areas leading to new infec-
tions prior to completion of the recommended vaccine
protocol. Lastly, while the Preventative Fraction figures re-
lated to seropositivity and vaccination status are extremely
compelling, they are not substitutes for data derived from
prospective, randomized, placebo-controlled studies. To
be clear, the data from the study described here were not
randomly collected, so it is not a comprehensive represen-
tation of the whole population.
Conclusions
In this analysis, the practice owner’s unique interest in
data-mining the hospital’s medical-record database to as-
sess the rate of new B. burgdorferi-positive test results over
a 5 year period is remarkable for its thoroughness and its
findings. Furthermore, this analysis compliments and buildsupon a previously published 21-month, 1,220 dog clinical
observation study that showed that previously-negative,
well vaccinated dogs rarely test positive for the presence of
C6 antibodies specific for infection with B. burgdorferi [14].
In conclusion, for all the years from 2009 to 2013, the vac-
cination condition (e.g. ‘fully’ vaccinated versus not) and
SNAP test results are not independent. We can there-
fore conclude that there is a strong, statistically signifi-
cant relationship between compliance with this
hospital’s immunization protocol using the canine re-
combinant OspA vaccine and the markedly low inci-
dence rate of new cases of B. burgdorferi-positive test
results (SNAP) in dogs [21].Abbreviations
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